Intuitive Surgical (ISRG) Set to Post Quarterly Earnings on Tuesday

Intuitive Surgical (NASDAQ:ISRG) is expected to be issuing its Q3 2026 results after the market closes on Tuesday, October 20th. Analysts expect the company to post earnings of $2.65 per share and revenue of $2.91 billion for the quarter. Interested persons are encouraged to explore the company’s upcoming Q3 2026 earnings overview page for the latest details on the call scheduled for Tuesday, October 20, 2026 at 4:30 PM ET.

Intuitive Surgical (NASDAQ:ISRG) last posted its earnings results on Thursday, July 16th. The medical equipment provider reported $2.80 EPS for the quarter, topping the consensus estimate of $2.48 by $0.32. The company had revenue of $2.89 billion during the quarter, compared to the consensus estimate of $2.83 billion. Intuitive Surgical had a net margin of 28.45% and a return on equity of 16.91%. The company’s revenue for the quarter was up 18.4% compared to the same quarter last year. During the same period in the previous year, the firm posted $1.81 earnings per share. On average, analysts expect Intuitive Surgical to post $8.87 EPS for the current fiscal year and $10.02 EPS for the next fiscal year.

Intuitive Surgical Trading Down 0.3%

NASDAQ ISRG opened at $426.70 on Friday. Intuitive Surgical has a 1 year low of $328.57 and a 1 year high of $603.88. The company has a fifty day simple moving average of $391.43 and a 200 day simple moving average of $409.74. The company has a market cap of $150.74 billion, a P/E ratio of 48.88, a P/E/G ratio of 3.22 and a beta of 1.46.

Analysts Set New Price Targets

Several equities analysts recently issued reports on the company. Raymond James Financial restated an “outperform” rating and set a $483.00 price target (down from $577.00) on shares of Intuitive Surgical in a research note on Friday, July 17th. Weiss Ratings reiterated a “hold (c)” rating on shares of Intuitive Surgical in a research report on Friday, August 14th. Oppenheimer upgraded Intuitive Surgical from a “market perform” rating to an “outperform” rating and set a $500.00 price objective for the company in a research report on Wednesday, August 12th. BMO Capital Markets reissued an “outperform” rating on shares of Intuitive Surgical in a report on Monday, July 20th. Finally, Truist Financial decreased their price objective on Intuitive Surgical from $580.00 to $510.00 and set a “buy” rating on the stock in a report on Thursday, July 16th. One equities research analyst has rated the stock with a Strong Buy rating, twenty-two have assigned a Buy rating, seven have issued a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus price target of $498.83.

Insider Activity

In other news, EVP Mark Brosius sold 77 shares of Intuitive Surgical stock in a transaction that occurred on Friday, August 21st. The shares were sold at an average price of $375.57, for a total value of $28,918.89. Following the completion of the transaction, the executive vice president owned 881 shares in the company, valued at approximately $330,877.17. The trade was a 8.04% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Gary Loeb sold 400 shares of the firm’s stock in a transaction on Monday, August 10th. The shares were sold at an average price of $379.00, for a total value of $151,600.00. Following the completion of the sale, the executive vice president owned 5,320 shares of the company’s stock, valued at approximately $2,016,280. This trade represents a 6.99% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last three months, insiders sold 12,370 shares of company stock valued at $4,891,989. Corporate insiders own 0.60% of the company’s stock.

Intuitive Surgical News Roundup

Here are the key news stories impacting Intuitive Surgical this week:

• Positive Sentiment: Analysts at Erste Group Bank raised their earnings estimates for ISRG, suggesting improved expectations for the company’s upcoming results and longer-term profitability. Erste Group Bank Analysts Boost Earnings Estimates for ISRG
• Positive Sentiment: Recent results have shown double-digit growth in robotic-surgery procedures, revenue and Intuitive Surgical’s installed base of systems. That underlying operating momentum remains a key support for the investment case despite the stock’s broader underperformance this year. Intuitive Surgical Valuation and Growth
• Positive Sentiment: The shares increased in the prior session and outperformed the broader market that day, reflecting some investor support ahead of the earnings release. ISRG Beats Stock Market Upswing
• Neutral Sentiment: Investors are focused on third-quarter procedure growth, da Vinci system demand, revenue, margins and other operating metrics—not just earnings per share and revenue—to determine whether recent momentum is sustainable. ISRG Ahead of Q3 Earnings
• Negative Sentiment: Expectations are tempered by slowing U.S. procedure growth and headwinds in China. These issues could pressure system placements and margins, increasing the risk of an earnings-related market reaction. ISRG Q3 Earnings Preview
• Negative Sentiment: Despite double-digit growth, shares have declined substantially during 2026 and trade at a premium valuation. Investors are questioning whether a valuation around 33 times expected earnings adequately reflects the company’s growth prospects, particularly if procedure growth slows. ISRG Valuation Analysis

About Intuitive Surgical

Intuitive Surgical, Inc develops and manufactures robotic-assisted systems and related technologies for minimally invasive surgery. Its products are designed to help surgeons perform procedures through small incisions while providing enhanced visualization, precision and control. The company’s primary platform is the da Vinci Surgical System, which is used across a range of specialties, including urology, gynecology, general surgery, cardiothoracic surgery and other procedures.

The company also offers the Ion endoluminal system, which is designed to support minimally invasive lung biopsy procedures.